Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.

Published

Journal Article (Review)

The fixed dose combination of abacavir with lamivudine represents a new treatment option for patients infected with HIV. Fixed dose combination abacavir/lamivudine has the convenience of one pill and once-daily dosing. It achieves comparable suppression of plasma HIV RNA with the pill's individual components dosed twice daily and with thymidine analogs combined with lamivudine. The combination is well tolerated, with the potential advantages of less lipoatrophy and fewer metabolic perturbations. However, the abacavir component may cause hypersensitivity reactions, which are reported in up to 8% of patients, and are potentially life threatening. Fixed dose combination abacavir/lamivudine should be considered as a viable treatment option for HIV-infected patients, particularly for those who have otherwise limited nucleoside reverse transcriptase inhibitor choices.

Full Text

Duke Authors

Cited Authors

  • Anderson, AML; Bartlett, JA

Published Date

  • December 2005

Published In

Volume / Issue

  • 3 / 6

Start / End Page

  • 871 - 883

PubMed ID

  • 16307500

Pubmed Central ID

  • 16307500

Electronic International Standard Serial Number (EISSN)

  • 1744-8336

Digital Object Identifier (DOI)

  • 10.1586/14787210.3.6.871

Language

  • eng

Conference Location

  • England